Manzo Pharmaceuticals reports successful lab test results for Lacto-Freedom
Aims to conduct a human clinical trial with the lactase-producing probiotic
Manzo Pharmaceuticals, a start-up specialist pharmaceutical company, is halfway through a six-month animal study on its lactase producing probiotic, Lacto-Freedom, and reports that the results of its tests have been successful, and bring the company and its partner, Celprogen, one step closer to human clinical trials.
Celprogen is conducting the six-month study to test the new probiotic treatment using laboratory rats, which are naturally lactose intolerant. After three months the rats given the treatment showed no negative side effects, even at very high doses. All doses from low to high concentration were successful at colonising the intestines and producing lactase, which enabled the rats to digest lactose, the company said.
The effect even lasted for three months after the administration of the probiotic was discontinued, which is said to be unique and superior to any other lactose intolerance treatment option currently on the market.
Jay Sharma, CEO of Celprogen, said the company would now like to run a clinical trial with a small number of human participants.
